East Windsor, NJ—The International Journal of Pharmacy & Pharmaceutical Research recently published a paper about a branded ingredient’s safety record in a small-animal study.
Sabinsa Corporation and Sami Labs founder Muhammed Majeed, Ph.D., lead researcher, concentrated on his company’s patented Coleus forskohlii extract (ForsLean). Groups of five male and female rats took 10% forskolin (as Forslean) at 2,000 mg/kg body weight and were observed for two weeks for any sign of toxicity. In a separate 28-day arm of the study, daily doses of 100, 300 and 1,000 mg/kg body were administered. Last, in another segment, groups of 20 male and 20 female rats took 10% forskolin for 180 days at daily dose levels of 500 mg/kg and 1,000 mg/kg body weight.
After all testing, no rats died and no major changes in hematology and serum biochemistry values were found between the active and control groups. In addition, body weight changes were normal, no organ damage was found and no signs of toxicity were uncovered.
The authors state, “In conclusion, the ‘No Observed Adverse Effect Level (NOAEL)’ of CF extract was determined to be above 1,000 mg/kg b.wt/day.”
Published in WholeFoods Magazine, Online 1/25/16